trending Market Intelligence /marketintelligence/en/news-insights/trending/SYdZr5ExxiKVns23Cu9WKQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bavarian Nordic gives details of share issue to J&J unit

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bavarian Nordic gives details of share issue to J&J unit

Bavarian Nordic A/S will issue 512,102 new shares of 10 Danish kroner each to Johnson & Johnson Innovation Inc. at a subscription price of 405.1578 kroner per share, as part of a collaboration agreement.

Janssen Pharmaceuticals recently agreed to invest $33 million in Bavarian Nordic as part of a broader agreement to use its technology to develop a vaccine for hepatitis B and another for HIV-1. Johnson & Johnson Innovation will subscribe for Bavarian Nordic shares worth $33 million, amounting to about 207.5 million kroner.

The new shares will be issued upon closing of the deal between Janssen and Bavarian Nordic, which is still awaiting clearance under the Hart-Scott-Rodino Act.

Janssen Pharmaceuticals is a unit of New Jersey-based Johnson & Johnson. Johnson & Johnson Innovation is an investment arm of J&J.

As of Aug. 9, US$1 was equivalent to 6.34 Danish kroner.